Moving Beyond the Avastin Incident:
The Continued Impact of Counterfeit Drugs in the United States

Last month, the U.S. Food and Drug Administration (FDA) issued a warning to healthcare professionals and patients that a counterfeit version of the cancer drug Avastin may have been purchased and used by some medical practices in the United States. Analysis showed that the fake cancer drug did not contain any of Avastin's active ingredient and instead contained substances ranging from starch and salt to solvent chemicals like acetone, which is used in paint thinner.

Please join the Partnership for Safe Medicines as we explore the continued impact of counterfeit drugs on Thursday, March 15 in the Congressional Visitor Center, Room HVC-201. This free luncheon briefing will start at noon and conclude at 1:30 p.m.

For more information, please contact Tara Goodin at 202-591-4041 or tara@safemedicines.org.